[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635249":3},{"organization":4,"armGroups":7,"interventions":33,"overallOfficials":58,"centralContacts":63,"locations":39,"responsibleParty":69,"collaborators":39,"id":71,"slug":39,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":39,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":39,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":39,"overallStatus":89,"whyStopped":39,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":39},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",[8,16,21,27],{"label":9,"type":10,"description":11,"interventionNames":12},"AD-211-L Group","EXPERIMENTAL","1 Week: twice daily; 2 tablets per dose (AD-211-L + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-L + placebo to AD-211-H + placebo to AD-2113).",[13,14,15],"Drug: AD-211-L","Drug: Placebo to AD-211-H","Drug: Placebo to AD-2113",{"label":17,"type":10,"description":18,"interventionNames":19},"AD-211-M Group","1 Week: twice daily; 2 tablets per dose AD-211-M + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-M + placebo to AD-211-H + placebo to AD-2113).",[20,14,15],"Drug: AD-211-M",{"label":22,"type":10,"description":23,"interventionNames":24},"AD-211-H Group","1 Week: twice daily; 2 tablets per dose (AD-211-M + placebo to AD-2113). 12 Weeks: twice daily; 3 tablets per dose (AD-211-H + placebo to AD-211-L\u002FM + placebo to AD-2113).",[20,25,26,15],"Drug: AD-211-H","Drug: Placebo to AD-211-L\u002FM",{"label":28,"type":29,"description":30,"interventionNames":31},"AD-2113 Group","ACTIVE_COMPARATOR","1 Week: twice daily; 2 tablets per dose (AD-2113 + placebo to AD-211-L\u002FM). 12 Weeks: twice daily; 3 tablets per dose (AD-2113 + placebo to AD-211-L\u002FM + placebo to AD-211-H).",[32,26,14],"Drug: AD-2113",[34,40,43,46,49,52,55],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DRUG","AD-211-L","Per oral, 1 tablet twice daily during the treatment period.",[9],null,{"type":35,"name":41,"description":37,"armGroupLabels":42,"otherNames":39},"AD-211-M",[22,17],{"type":35,"name":44,"description":37,"armGroupLabels":45,"otherNames":39},"AD-211-H",[22],{"type":35,"name":47,"description":37,"armGroupLabels":48,"otherNames":39},"AD-2113",[28],{"type":35,"name":50,"description":37,"armGroupLabels":51,"otherNames":39},"Placebo to AD-211-L\u002FM",[22,28],{"type":35,"name":53,"description":37,"armGroupLabels":54,"otherNames":39},"Placebo to AD-211-H",[9,17,28],{"type":35,"name":56,"description":37,"armGroupLabels":57,"otherNames":39},"Placebo to AD-2113",[22,9,17],[59],{"name":60,"affiliation":61,"role":62},"Jung Yoon Choi","Daegu Catholic University Medical Center","PRINCIPAL_INVESTIGATOR",[64],{"name":65,"role":66,"phone":67,"phoneExt":39,"email":68},"Hyeji Lee","CONTACT","+82318915604","hjlee@addpharma.co.kr",{"type":70,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100635249",false,"NCT07550231","Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee","A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee","Inclusion Criteria:\n\n* Signed informed consent\n* Patients with osteoarthritis of the Knee\n* Other inclusions applied\n\nExclusion Criteria:\n\n* Patients with secondary osteoarthritis of the knee\n* Other exclusions applied","ALL","19 Years","75 Years",{"count":81,"type":82},200,"ESTIMATED","INTERVENTIONAL",[85],"PHASE2","The purpose of this study is to determine the optimal dose of AD-211 in patients with osteoarthritis of the knee.",[88],"Osteoarthritis of the Knees","NOT_YET_RECRUITING","2026-04-20",{"date":92,"type":93},"2026-04-24","ACTUAL",{"date":95,"type":82},"2026-06",{"date":97,"type":82},"2027-03",{"name":5,"class":6}]